Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CTSL | P07711 | 4/20 | 0.33 |
| ▸ | CTSB | P07858 | 4/20 | 0.33 |
| ▸ | CTSH | P09668 | 3/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27991241 | 1.00 | CTSK (0.37) | CTSKTSHRCTSLCTSBCTSH | |
| SCHEMBL12631778 | 0.98 | CTSK (0.39) | CTSKCTSLCTSBCTSHLTA4H | |
| SCHEMBL6156682 | 0.98 | CTSK (0.39) | CTSKCTSLCTSBCTSHLTA4H | |
| SCHEMBL14261875 | 0.98 | CTSK (0.39) | CTSKCTSLCTSBCTSHLTA4H | |
| SCHEMBL18125093 | 0.90 | — | — | |
| SCHEMBL4284276 | 0.90 | — | — | |
| SCHEMBL14928915 | 0.90 | — | — | |
| SCHEMBL114230 | 0.87 | CTSK (0.35) | CTSKCTSLCTSBCTSHLTA4H | |
| SCHEMBL15662421 | 0.83 | TSHR (0.36) | TSHR | |
| SCHEMBL3155857 | 0.81 | CYP1A2 (0.40) | CTSKCTSLCTSBCTSHLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570115-B2 | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-02-25 | — | — | US | disclosed |
| US-20180093969-A1 | Modulator of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulator | VERTEX PHARMACEUTICALS INCORPORATED | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570115-B2 | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | CFTR, SLC26A4, ABCB11 | CTSK 2230/4885TSHR 1168/4885CTSL 2359/4885 |
| US-20180093969-A1 | Modulator of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulator | CFTR, SLC26A4, ABCB11 | CTSK 2230/4885TSHR 1168/4885CTSL 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.